Discloses isolated human cyclin A1 (CCNA1)-specific T cell comprising at least one recombinant expression vector encoding a T-cell receptor polypeptide that specifically binds in a human class I HLA-restricted manner to a CCNA1 polypeptide epitope of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, or 9 amino acids comprising the amino acid sequence set forth in SEQ ID NO:1, 3, 4, 5, 6, or 8. Further discloses compositinos suitable for use in the ex vivo manufacture of a medicament for treating a condition characterized by CCNA1 overexpression in cells of a subject.
